focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMCS.L Share News (MCS)

  • There is currently no data for MCS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

McCarthy & Stone swings to loss because of Covid-19

Wed, 15th Jul 2020 10:00

(Sharecast News) - McCarthy & Stone said the impact of Covid-19 would be weighted towards the second half of the year as lower sales during the crisis drove it to a loss in the first half.
The retirement home builder reported a £24.8m underlying operating loss for the six months to the end of April compared with a £21.3m profit a year earlier. Revenue fell 64% to £101.1m.

McCarthy & Stone swung to a pretax loss of £91.3m from a £3.6m profit the year before, mainly because of £63.4m of exceptional items including £60.4m of goodwill and brand impairment. It also announced the abrupt departure of joint chief operating officer Nigel Turner.

The company said the first half was split into three distinct phases. After a weak end to the 2019 calendar year because of the general election business picked up in January and February following the clear election result but then subsided in March and April as the Covid-19 pandemic spread and sales offices and building sites were shut down.

McCarthy & Stone said the peak of the crisis was past but that the effect on its finances would be more severe in the second half. It kept financial guidance on hold.

"Given the significant level of ongoing uncertainty, the board currently have little visibility as to the expected FY20 outturn," the company said. "Guidance therefore remains suspended until we have greater clarity of the Covid-19 impact on the business and wider UK economy."

The company said the Covid-19 crisis had vindicated its model of building homes for people to live independently in retirement because far fewer of its residents had caught the disease than those in care homes. It said reform of social care, the holiday for land stamp duty and proposed planning relaxation showed government was listening to its views.

Chief Executive John Tonkiss said: "Working with government, we want to develop a long-term plan to provide more options to keep older people safe at home, rather than in a home, and ensure this is fully understood by the public. We are pleased that this call is beginning to be heard."

McCarthy & Stone said it had parted company with Turner with immediate effect just 19 months after he joined to oversee the building division. The company said it wanted a smaller team and that many of Turner's projects had been completed. Mike Lloyd will remain COO for sales, customers and services and building managers will report directly to Tonkiss.

Tonkiss said: "I would like to thank Nigel for his hard work and enthusiasm since joining us and he has helped us make significant progress with delivering our new strategy. This includes leading our build cost reduction activity ... and driving material change in our effective management of health and safety. We wish him the very best for the future."

The company's shares fell 1.1% to 73.6p at 10:34 BST.







More News
27 Oct 2020 09:34

UK BROKER RATINGS SUMMARY: Analysts Positive On The Hut Group

UK BROKER RATINGS SUMMARY: Analysts Positive On The Hut Group

Read more
26 Oct 2020 13:46

Monday broker round-up

(Sharecast News) - Pearson: UBS upgrades to buy with a target price of 650p.

Read more
26 Oct 2020 09:44

UK BROKER RATINGS SUMMARY: UBS And Barclays Raise McCarthy & Stone

UK BROKER RATINGS SUMMARY: UBS And Barclays Raise McCarthy & Stone

Read more
26 Oct 2020 08:02

LONDON BRIEFING: Buoyant Hut Group Raises Annual Revenue Guidance

LONDON BRIEFING: Buoyant Hut Group Raises Annual Revenue Guidance

Read more
25 Oct 2020 12:39

Sunday newspaper round-up: Coronavirus vaccine, UK-US trade, Shell

(Sharecast News) - Plans are being drawn up for frontline NHS staff to receive a coronavirus vaccine within weeks, as the Government moves to accelerate the timetable for a mass roll-out. An email sent by an NHS Trust chief to his staff, seen by The Mail on Sunday, reveals the Health Service is preparing for a national vaccination programme before Christmas. - Mail on Sunday

Read more
23 Oct 2020 11:00

Canaccord Genuity raises target price on McCarthy & Stone

(Sharecast News) - Analysts at Canaccord Genuity raised their target price on homebuilder McCarthy & Stone from 80.0p to 115.0p on Friday following today's unexpected offer from private equity group Lone Star.

Read more
23 Oct 2020 09:30

TOP NEWS: McCarthy & Stone Accepts GBP630 Million Offer From Lone Star

TOP NEWS: McCarthy & Stone Accepts GBP630 Million Offer From Lone Star

Read more
23 Oct 2020 07:55

PE firm Lone Star to buy McCarthy & Stone for £630m

(Sharecast News) - McCarthy & Stone has agreed to be bought by US private equity group Lone Star in a deal that values the retirement housebuilder at £630m.

Read more
23 Oct 2020 07:53

LONDON MARKET PRE-OPEN: Barclays Quarterly Profit Up But No Payout Yet

LONDON MARKET PRE-OPEN: Barclays Quarterly Profit Up But No Payout Yet

Read more
9 Oct 2020 09:34

UK BROKER RATINGS SUMMARY: Barclays Initiates Housebuilder Ratings

UK BROKER RATINGS SUMMARY: Barclays Initiates Housebuilder Ratings

Read more
1 Oct 2020 10:15

McCarthy & Stone Partners With Non-Profit For Later Life Housing

McCarthy & Stone Partners With Non-Profit For Later Life Housing

Read more
15 Jul 2020 12:24

Wednesday broker round-up

(Sharecast News) - Royal Dutch Shell: JP Morgan downgrades to neutral with a target price of 1,700.0p.

Read more
15 Jul 2020 12:03

McCarthy & Stone Swings To First Half Loss, Suspends Dividend

McCarthy & Stone Swings To First Half Loss, Suspends Dividend

Read more
14 Jul 2020 13:42

Wednesday preview: Covid-19 vaccines, Burberry in focus

(Sharecast News) - The focus in markets is likely to be on the news-flow around potential Covid-19 vaccines following confirmation that a third phase clinical trial for Moderna Therapeutics's vaccine treatment will go ahead in July as scheduled.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.